Bio-Thera(SH:688177) Zheng Quan Zhi Xing·2025-08-21 05:39Core Viewpoint - The company plans to use up to RMB 100 million of idle raised funds to temporarily supplement its working capital, ensuring that this does not affect the progress of its investment projects and complies with relevant regulations [19][20][21]. Fundraising Overview - The company raised a total of RMB 2 billion through the issuance of 60 million shares at RMB 32.76 per share, with the funds verified by Ernst & Young [2][3]. - The funds are stored in a special account and managed under a tripartite supervision agreement with the sponsor and the bank [3]. Investment Project Situation - The company has outlined its investment priorities in its prospectus, with a total expected fundraising usage of RMB 2 billion [4]. - If the actual net amount raised is less than the total required for the projects, the company will use self-raised funds to cover the shortfall [4]. Previous Use of Idle Funds - The company has previously used idle funds for cash management and to temporarily supplement working capital, with amounts up to RMB 1 billion approved in various instances [6][8][10][12][14]. - All previously used funds for temporary working capital have been returned to the special account by the specified deadlines [6][8][12][14]. Current Proposal for Idle Funds - The current proposal allows for the use of up to RMB 100 million of idle funds for working capital, with a usage period not exceeding 12 months [19][20]. - The funds will be used solely for business expansion and daily operations related to the company's main business, without affecting the investment plans [19]. Approval Process - The proposal was approved by the board of directors and complies with relevant laws and regulations, ensuring the protection of shareholder interests [20][21]. - The audit committee has also expressed agreement with the proposal, confirming that it aligns with the company's operational and financial strategies [20][21].